PACAP (pituitary adenylate cyclase-activating polypeptide) is a 38-amino acid neuropeptide (PACAP-38) with a shorter 27-amino acid form (PACAP-27). Discovered in 1989, PACAP is one of the most potent neurotrophic factors known and signals through three receptor types: PAC1 (VPAC2), VPAC1, and VPAC2[@vaudry1999]. While PACAP shares VPAC1 and VPAC2 receptors with VIP, its exclusive PAC1 receptor activation provides distinct signal transduction pathways — particularly robust PLC/IP3/Ca²⁺ signaling and PKC activation — that confer unique neuroprotective properties.
PACAP's neuroprotective profile is exceptionally broad: it protects against oxidative stress, excitotoxicity, neuroinflammation, mitochondrial dysfunction, and apoptosis while promoting neurogenesis and synaptic plasticity. Evidence spans Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), ischemic injury, and 4R-tauopathies including CBS/PSP[@shioda2017].
PACAP and VIP share VPAC1 and VPAC2 receptors, but PACAP uniquely activates PAC1 (VPAC2) receptors with high affinity. PAC1 receptors couple to both Gαs (cAMP/PKA) and Gαq (PLC/IP3/PKC) pathways, while VPAC receptors primarily signal through Gαs[@harmar2012]. This dual-coupling capability makes PACAP's signal transduction more diverse and potent than VIP alone.
| Feature |
PACAP |
VIP |
| PAC1 receptor |
High affinity |
None |
| VPAC1 receptor |
High affinity |
High affinity |
| VPAC2 receptor |
High affinity |
High affinity |
| Primary G coupling |
Gαs + Gαq |
Gαs |
| Calcium signaling |
Strong (via PLC/IP3) |
Weak |
| PKC activation |
Yes |
Limited |
| Neuroprotective potency |
Higher |
Moderate |
PACAP receptor activation produces multi-faceted neuroprotection:
Like VIP, PACAP activates adenylyl cyclase via Gαs, raising cAMP and activating PKA. This phosphorylates CREB, driving transcription of neuroprotective genes: BDNF, SOD, catalase, and Bcl-2[@brennan2004][@rat2011].
PAC1 receptors couple to Gαq, activating phospholipase C (PLC), which cleaves PIP2 into IP3 and DAG. IP3 triggers Ca²⁺ release from endoplasmic reticulum, while DAG activates PKC. This pathway drives[@somogyvari2012]:
- MAPK/ERK activation for cell survival
- NF-κB modulation for anti-inflammatory effects
- Synaptic plasticity and memory consolidation
- Enhanced gene transcription beyond cAMP alone
PACAP upregulates expression and activity of antioxidant enzymes — SOD, glutathione peroxidase, catalase — protecting neurons from reactive oxygen species (ROS) that accumulate in neurodegenerative conditions[@tamas2002].
PACAP prevents mitochondrial apoptosis through multiple mechanisms:
- Bcl-2 upregulation and Bad phosphorylation
- Caspase-3 inhibition
- cytochrome c release blockade
- Preservation of mitochondrial membrane potential[@d2002]
PACAP exerts potent anti-inflammatory effects by[@liu2019]:
- Inhibiting NF-κB in microglia and astrocytes
- Suppressing iNOS and COX-2 expression
- Reducing TNF-α, IL-1β, IL-6 production
- Shifting microglia from M1 to M2 phenotype
- Promoting IL-10 and TGF-β release
PACAP addresses core AD pathology through multiple mechanisms[@tamas2002][@masmoudi2003]:
- Amyloid pathology: PACAP reduces Aβ-induced neurotoxicity, promotes non-amyloidogenic APP processing via α-secretase activation, and enhances microglial Aβ phagocytosis and clearance
- Tau hyperphosphorylation: PACAP-activated Akt and PKC pathways inhibit GSK-3β, reducing tau phosphorylation
- Oxidative stress: PACAP enhances antioxidant enzyme expression, protecting neurons from Aβ-induced oxidative damage
- Synaptic dysfunction: PACAP promotes synaptic plasticity through PKC-dependent mechanisms, enhancing LTP and dendritic spine density[@han2018]
- Cholinergic protection: PACAP protects basal forebrain cholinergic neurons vulnerable in AD
PACAP provides dopaminergic neuroprotection across multiple PD models[@reglodi2000][@wang2006]:
- Dopaminergic neuron survival: PACAP protects TH-positive neurons in substantia nigra from 6-OHDA and MPTP toxicity
- Mitochondrial function: PACAP preserves Complex I activity, which is specifically impaired in PD
- Alpha-synuclein modulation: PACAP enhances autophagic clearance of alpha-synuclein aggregates through mTOR-independent pathways[@chen2012][@deguen2015]
- Neuroinflammation: Suppresses microglial activation in substantia nigra pars compacta
- Motor behavior: PACAP treatment improves motor performance in PD animal models
- Gene therapy: AAV-mediated PACAP delivery shows sustained neuroprotection in PD models[@chen2020]
PACAP extends survival and protects motor neurons in ALS models[@ha2006]:
- Motor neuron protection: PACAP prevents apoptotic death of spinal motor neurons
- Glial modulation: Reduces harmful activation of astrocytes and microglia
- SOD1 models: Extends survival in transgenic SOD1 mutant mice
- Excitotoxicity: Protects against glutamate-induced excitotoxicity
- Axonal integrity: Preserves neuromuscular junction structure
PACAP shows particular promise in 4R-tauopathies including corticobasal syndrome and progressive supranuclear palsy[@fang2019]:
- Tau pathology: PACAP reduces tau phosphorylation and aggregation in tauopathy models
- Neuroprotection: Protects cortical and brainstem neurons vulnerable in PSP
- Neuroinflammation: Modulates glial activation in tauopathy pathology
- Autophagy enhancement: Promotes clearance of pathological tau species
- Autonomic dysfunction: PACAP regulates autonomic functions affected in CBS/PSP
¶ Ischemic Stroke and Acute Neuroprotection
PACAP is one of the most potent endogenous neuroprotective peptides against ischemic injury[@fall2009]:
- Infarct reduction: PACAP reduces cerebral infarct volume in focal ischemia models
- Blood-brain barrier protection: Preserves BBB integrity after stroke
- Anti-apoptotic: Prevents post-ischemic neuronal death
- Anti-inflammatory: Reduces post-ischemic neuroinflammation
- Time window: Effective when administered within critical time windows
flowchart TD
A["PACAP"] --> B["PAC1 Receptor"]
A --> C["VPAC1"]
A --> D["VPAC2"]
B --> E["Gαs"]
B --> F["Gαq"]
C --> E
D --> E
E --> G["↑cAMP"]
E --> H["PKA"]
H --> I["p-CREB"]
I --> J["Gene Transcription\nBDNF, Bcl-2, SOD"]
F --> K["PLC"]
K --> L["IP3"]
K --> M["DAG"]
L --> N["↑Ca²⁺"]
M --> O["PKC"]
O --> P["ERK1/2\nCell Survival"]
P --> Q["Anti-apoptotic\nSynaptic Plasticity"]
J --> Q
J --> R["Neuroprotection"](/therapeutics/neuroprotection)
P --> S["NF-κB Inhibition"]
S --> T["Anti-inflammatory\nMicroglia M2 shift"]
G --> U["Epac"]
U --> V["Rap1"]
V --> W["PI3K/Akt"]
W --> X["mTOR\nAutophagy"]
W --> Y["GSK-3β Inhibition"]
Y --> Z["↓Tau Phosphorylation"]
X --> AA["Autophagy\nProtein Clearance"]
¶ Drug Candidates and Development
| Drug |
Target |
Stage |
Indication |
Notes |
| Maxadilan |
PAC1 |
Preclinical |
PD, ALS |
PAC1-selective agonist; potency confirmed |
| PACAP-38 |
PAC1/VPAC1/VPAC2 |
Preclinical |
AD, PD, stroke |
Endogenous peptide; broad-spectrum |
| Aviptadil |
VPAC1/VPAC2 |
Phase 2 |
AD, PD |
VIP analog; not PAC1-selective |
| Synthetic PACAP analogs |
PAC1/VPAC |
Preclinical |
Various |
Stabilized against proteolysis |
Maxadilan is a 61-amino acid peptide from sand fly salivary glands that is a highly selective PAC1 agonist[@hadley2023]:
- Mechanism: PAC1-specific agonist with no VPAC activity
- Potency: Among the most potent PAC1 agonists known
- BBB penetration: Some CNS penetration demonstrated
- Challenges: Non-human sequence, potential immunogenicity
- Status: Preclinical development for neuroprotection
Engineered PACAP analogs aim to overcome the peptide's limitations[@hadley2023]:
- Stability engineering: D-amino acid substitutions, cyclization, peptidomimetics to resist proteolysis (t½ < 5 min for native PACAP-38)
- Selectivity: PAC1-selective vs. mixed VPAC agonists
- BBB enhancement: Conjugation to brain-targeting vectors
- Intranasal formulation: Direct nose-to-brain delivery bypasses BBB
- Gene therapy: AAV-mediated PACAP expression for sustained delivery
AAV-mediated PACAP delivery represents a promising approach for sustained neuroprotection[@chen2020]:
- Single-dose AAV injection provides long-term PACAP expression
- Demonstrated efficacy in PD and stroke models
- Avoids need for repeated peptide administration
- Challenges: viral delivery, immune response, dosing
PACAP-based therapies face significant delivery hurdles:
- Short half-life: Native PACAP-38 has t½ < 5 minutes due to proteolytic degradation (dipeptidyl peptidase IV, neprilysin)
- Blood-brain barrier: Limited passive diffusion requires active transport or disruption strategies
- Receptor desensitization: PAC1 receptors internalize with chronic exposure
- Dosing: Optimal therapeutic window narrow — receptor saturation vs. desensitization
Researchers are pursuing multiple approaches[@hadley2023]:
- Intranasal delivery: Bypasses BBB for direct nose-to-brain transport; effective in stroke and PD models
- Peptide engineering: Stabilized analogs with extended half-life (24+ hours achieved in some constructs)
- Focused ultrasound: Temporary BBB opening for enhanced brain penetration
- Nanoparticle encapsulation: Targeted delivery to neurons
- Cell-penetrating peptides: Fusion constructs for improved BBB transit
- Gene therapy: Viral vectors for constitutive expression
- Pump systems: Continuous infusion for sustained exposure
While PACAP and VIP share VPAC receptors, PACAP's unique PAC1 signaling provides advantages:
| Property |
PACAP |
VIP |
| PAC1 activation |
Yes |
No |
| Signaling breadth |
cAMP + Ca²⁺/PKC |
cAMP primarily |
| Neuroprotective potency |
Higher |
Moderate |
| Anti-inflammatory |
Potent |
Moderate |
| Autophagy induction |
Yes |
Limited |
| Synaptic plasticity |
Strong (PKC-mediated) |
Moderate |
| Delivery difficulty |
High |
High |
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) share some mechanisms with PACAP but differ:
| Feature |
PACAP |
GLP-1 Agonists |
| Receptor |
PAC1, VPAC1, VPAC2 |
GLP-1R |
| G protein |
Gαs + Gαq |
Gαs |
| CNS penetration |
Limited (improved delivery needed) |
Moderate |
| Clinical track record |
Preclinical |
Some in Phase 2 for AD |
| Potency in CNS |
Higher |
Moderate |
| Peripheral effects |
Minimal |
GI, weight loss |
¶ Side Effects and Safety
PACAP has shown favorable safety profiles in preclinical and early clinical studies:
- Common: Mild transient effects at high doses
- Vascular effects: PACAP can cause vasodilation and hypotension via VPAC receptors
- GI effects: Nausea, intestinal motility changes
- No significant toxicity: Long-term administration in animal models shows good tolerability
- VIPoma or PACAP-secreting tumors
- Uncontrolled hypotension
- Severe cardiovascular disease
PACAP's broad neuroprotective profile makes it attractive across multiple conditions:
| Disease |
Key Mechanism |
Development Stage |
| AD |
Anti-amyloid, synaptic plasticity, tau |
Preclinical |
| PD |
Dopaminergic protection, autophagy |
Preclinical + gene therapy |
| ALS |
Motor neuron survival, glial modulation |
Preclinical |
| CBS/PSP |
Tau modulation, neuroprotection |
Preclinical |
| Stroke |
Acute neuroprotection |
Preclinical |
| Traumatic brain injury |
Neuroprotection, repair |
Preclinical |
- Vaudry et al., PACAP and its receptors (1999)
- Brennan et al., PACAP neuroprotection against excitotoxicity (2004)
- Reglodi et al., PACAP protects against 6-OHDA toxicity (2000)
- Tamas et al., PACAP reduces oxidative stress in AD (2002)
- Masmoudi et al., PACAP and Aβ neurotoxicity (2003)
- Wang et al., PACAP attenuates MPTP toxicity (2006)
- Ha et al., PACAP prevents motor neuron death in ALS (2006)
- Fall et al., PACAP in ischemic stroke (2009)
- Rat et al., PAC1 receptor signaling (2011)
- Chen et al., PACAP and autophagic clearance in PD (2012)
- Deguen et al., PACAP and autophagy (2015)
- Shioda et al., PACAP signaling for neuroprotection (2017)
- Fang et al., PACAP in tauopathies and PSP (2019)
- Hadley et al., PACAP analogs for CNS delivery (2023)
- Harmar et al., VPAC receptors (2012)
- Liu et al., PACAP and neuroinflammation in AD (2019)
- Chen et al., PACAP gene therapy for PD (2020)
- Di Cora et al., PACAP effects on mitochondria (2002)
- Somogyvari-Vigher et al., PACAP receptors: structure to therapy (2012)
- Han et al., PACAP and synaptic plasticity (2018)